Show simple item record

dc.contributor.authorClamp, Andrew R
dc.contributor.authorMcNeish, I
dc.contributor.authorDean, A
dc.contributor.authorGallardo, D
dc.contributor.authorWeon-Kim, J
dc.contributor.authorO'Donnell, D
dc.contributor.authorHook, J
dc.contributor.authorCoyle, C
dc.contributor.authorBlagden, S
dc.contributor.authorBrenton, J
dc.contributor.authorNaik, R
dc.contributor.authorPerren, T
dc.contributor.authorSundar, S
dc.contributor.authorCook, A
dc.contributor.authorJames, E
dc.contributor.authorSwart, A
dc.contributor.authorStenning, S
dc.contributor.authorKaplan, R
dc.contributor.authorLedermann, J
dc.date.accessioned2017-11-21T21:33:02Z
dc.date.available2017-11-21T21:33:02Z
dc.date.issued2017-09
dc.identifier.citation929O_PRICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx440.039
dc.identifier.urihttp://hdl.handle.net/10541/620638
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.039/4109951/929OPRICON8-A-GCIG-phase-III-randomised-trialen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title929O_PR ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record